Article info

other Versions

Download PDFPDF

Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis

Authors

  • Han Gong Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China PubMed articlesGoogle scholar articles
  • Dan Nie Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of ChinaDepartment of Obstetrics and Gynecology, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China PubMed articlesGoogle scholar articles
  • Yue Huang West China School of Medicine, Sichuan University, Chengdu, People's Republic of China PubMed articlesGoogle scholar articles
  • Zhengyu Li Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Zhengyu Li, West China Second University Hospital, Sichuan University, No. 20 Section 3, Renmin South Road, Chengdu, Sichuan 610041, People’s Republic of China; zhengyuli{at}scu.edu.cn
View Full Text

Citation

Gong H, Nie D, Huang Y, et al
Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis

Publication history

  • Received March 11, 2020
  • Revision received July 16, 2020
  • Accepted July 17, 2020
  • First published August 19, 2020.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.